Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
Are there SEC filings, whistleblower complaints, or litigation documents in the past two years that reference Neurocept?
Executive summary
Available filings show routine SEC reports and investor documents for Neurocrine Biosciences (ticker NBIX) — including 10‑K/10‑Q and proxy (DEF 14A) materials filed within the past two years — accessible via Neurocrine’s investor site and EDGAR [1] [2] [3] [4]. Search results do not show whistleblower complaints or litigation records specifically naming “Neurocept”; consumer complaint pages and review sites mention a product called Neurocept, but those are consumer reviews/scam reports, not SEC, whistleblower, or court filings [5] [6].
1. What the SEC record shows for Neurocrine Biosciences (corporate filings)
Neurocrine Biosciences maintains a standard set of SEC filings and investor documents: its investor relations site lists SEC filings and annual reports (including 2024 and earlier) and provides access to proxy statements and DEF 14A filings such as the April 10, 2024 DEF 14A referenced on the company site [1] [7] [3]. Aggregators and EDGAR index pages also show NBIX SEC filings (10‑K/10‑Q), for example Nasdaq’s SEC filings page and EDGAR’s Neurocrine browse entry [2] [4]. Independent filing aggregators archive Neurocrine 10‑K forms (a 2025 10‑K accession is listed by Last10K as filed Feb 10, 2025) [8].
2. No explicit SEC, whistleblower, or litigation hits for “Neurocept” in these sources
The search results provided do not contain any SEC enforcement, whistleblower complaint, or litigation document that names “Neurocept.” The documents and pages cited concern Neurocrine Biosciences’ routine regulatory and investor disclosures [1] [2] [3] [4]. Available sources do not mention any SEC filings, whistleblower complaints, or court filings that reference a product or company called “Neurocept.”
3. Consumer complaints and scam reports reference a product named Neurocept — but these are not formal SEC or court filings
Separate search results show consumer-facing complaint and review postings about a supplement or product called Neurocept: a Better Business Bureau scam tracker entry alleging an AI-driven scam and Trustpilot reviews alleging false endorsements and product problems [5] [6]. These pages reflect consumer complaints and alleged scams, not SEC whistleblower submissions or litigation dockets. The sources themselves do not claim these consumer complaints have produced SEC enforcement actions or court cases [5] [6].
4. Possible confusion between Neurocrine (NBIX) and “Neurocept” — check entity identity and scope
The materials that show formal SEC filings in the provided results all refer to Neurocrine Biosciences (NBIX) or other companies (e.g., NeuroPace, Neuronetics) with established SEC CIKs and filings [1] [2] [8] [4] [9]. “Neurocept” as a product name appears only in consumer review and scam-tracking contexts in these results, suggesting a likely distinction: Neurocrine is a publicly traded biotech subject to SEC reporting, while “Neurocept” appears in marketplace/consumer complaint threads [1] [5] [6]. Available sources do not mention any corporate connection between Neurocrine and Neurocept.
5. Where the trail goes next — recommended checks and limitations
To be certain whether any enforcement, whistleblower, or litigation documents reference Neurocept (or tie it to a particular legal entity), check: (a) EDGAR search for the exact term “Neurocept” across all filings; (b) PACER and state court dockets for lawsuits mentioning Neurocept; (c) agency whistleblower portals (SEC, OSHA, HHS Office of Inspector General) for complaints that might use different entity names; and (d) consumer protection/attorney general actions in states where Neurocept sales were reported. The sources supplied do not include EDGAR search hits for “Neurocept” or any PACER/state docket entries (available sources do not mention searches beyond those shown) [4] [5] [6].
6. Context and competing viewpoints in the sources
Public-company filings cited (Neurocrine investor site, DEF 14A, 10‑K/10‑Q aggregations) are corporate disclosures meant to inform investors about business operations, risks, and governance [1] [8] [3]. Consumer complaints about Neurocept present the opposing viewpoint — alleging scams, AI‑generated endorsements, and misrepresentation [5] [6]. The provided reporting does not reconcile those perspectives or show a legal escalation from consumer complaints into SEC or court action in the sources given (available sources do not mention such escalation) [5] [6] [4].
Conclusion: In the materials supplied, formal SEC filings and proxy documents exist for Neurocrine Biosciences, but the name “Neurocept” appears only in consumer complaint and review pages; no SEC enforcement, whistleblower complaint, or litigation document referencing “Neurocept” appears in the provided sources [1] [2] [3] [4] [5] [6].